Lawsuit Overview
<p align= justify >According to a press release dated June 19, 2007, the complaint charges Neurocrine and certain of its officers and directors with violations of the Securities Exchange Act of 1934. Neurocrine engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. During the Class Pe...
You must register (for free) or login to view the entire case.